BRIEF published on 08/28/2024 at 09:05, 1 year 3 months ago Le Dr Jörg Schüttrumpf démissionne du conseil d'administration de Biotest AG Conseil D'administration Biotest AG Développement De Produits Jörg Schüttrumpf Groupe Grifols
PRESS RELEASE published on 08/28/2024 at 09:00, 1 year 3 months ago Dr. Jörg Schüttrumpf resigns from the Management Board of Biotest AG Dr. Jörg Schüttrumpf resigns as Chief Scientific Officer of Biotest AG to focus on role as Chief Scientific Innovation Officer of Grifols Group, effective August 31, 2024 Resignation Management Board Biotest AG Grifols Group Dr. Jörg Schüttrumpf
BRIEF published on 08/06/2024 at 09:05, 1 year 3 months ago Biotest Sees 35% Sales Spike in First Half of 2024 Financial Results Revenue Growth FDA Approval Biotest Yimmugo®
BRIEF published on 08/06/2024 at 09:05, 1 year 3 months ago Biotest voit ses ventes augmenter de 35 % au premier semestre 2024 Résultats Financiers Hausse Des Revenus Approbation De La FDA Biotest Yimmugo®
PRESS RELEASE published on 08/06/2024 at 09:00, 1 year 3 months ago Biotest increases sales in the first half of 2024 by 35% to Euro 372 million Biotest AG reports 35% sales increase to Euro 372 million in H1 2024. EBIT reaches Euro 78.4 million. FDA approves Yimmugo® and BNL facility. Positive revenue and earnings growth Revenue Growth FDA Approval Sales Increase Biotest AG H1 2024
BRIEF published on 07/30/2024 at 08:05, 1 year 4 months ago Biotest Reports 35% Increase in Sales for First Half of 2024 Financial Results Revenue Increase FDA Approval Sales Growth Biotest AG
BRIEF published on 07/30/2024 at 08:05, 1 year 4 months ago Biotest annonce une augmentation de 35 % de ses ventes pour le premier semestre 2024 Résultats Financiers Approbation De La FDA La Croissance Des Ventes Augmentation Des Revenus Biotest SA
PRESS RELEASE published on 07/30/2024 at 08:00, 1 year 4 months ago Biotest increases sales in the first half of 2024 by 35% to Euro 372 million Biotest AG increases sales by 35% to Euro 372 million in the first half of 2024. EBIT reaches €78.4 million. FDA approval received. Strategic deal with Kedrion estimated to yield $1 billion in 7 years FDA Approval EBIT Sales Increase Biotest AG €372 Million
BRIEF published on 07/01/2024 at 09:05, 1 year 5 months ago Biotest AG Prepares Yimmugo Launch in the USA, Secures Strategic Deal with Kedrion FDA Approval Biotest AG Yimmugo Kedrion Immunoglobulin
BRIEF published on 07/01/2024 at 09:05, 1 year 5 months ago Biotest AG prépare le lancement de Yimmugo aux États-Unis et conclut un accord stratégique avec Kedrion Approbation De La FDA Yimmugo Biotest SA Kedrion Immunoglobuline
Published on 12/05/2025 at 21:45, 1 hour 38 minutes ago When the Architecture Becomes Visible: The SMX Revaluation Explained
Published on 12/05/2025 at 21:30, 1 hour 53 minutes ago The Identity Layer Beneath Everything: Why Markets Are Revaluing SMX All at Once
Published on 12/05/2025 at 21:20, 2 hours 3 minutes ago Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Published on 12/05/2025 at 21:00, 2 hours 23 minutes ago The Repricing Event: Why Multiple Global Industries Are Suddenly Moving Toward SMX
Published on 12/05/2025 at 22:15, 1 hour 7 minutes ago CPI PROPERTY GROUP - Changes in Shareholding and Board of Directors
Published on 12/05/2025 at 22:12, 1 hour 10 minutes ago EQS-Adhoc: CPI PROPERTY GROUP - Change to Distribution Policy
Published on 12/05/2025 at 18:58, 4 hours 24 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:15, 5 hours 7 minutes ago Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 23:00, 23 minutes ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 23 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 23 minutes ago ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 23:00, 23 minutes ago ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 17:18, 6 hours 5 minutes ago La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
